Small molecule · Degrader of Bruton's tyrosine kinase (BTK) · developed by AbbVie
ABBV-101 is an orally bioavailable protein degrader that links an E3 ubiquitin ligase binder to a BTK-binding moiety. It drives ubiquitination and proteasomal degradation of Bruton's tyrosine kinase, blocking B-cell receptor signaling in malignant B-cells. It is being studied in hematologic cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05753501 | Phase 1 | Hematologic Cancer | Active not recruiting | ABBV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hematologic Cancer
See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ABBV catalysts and pipeline →